Engineered EVs (EEVs) are an emerging form of precision medicine with immense promise and application in key areas such as neurology, cardiology and oncology. EEVs can be directed to certain cell types and carry powerful cargos, such as RNA, enzymes and/or small molecules. Because of their cellular provenance, EEVs avoid critical limitations of other delivery vehicles such as liposomes and other synthetic nanoparticles. Exopharm has a number of EEV projects under development including Fortrexo for combating viral infections and Cognevo for the delivery of drugs to the central nervous system.
Exopharm’s EVPS technology was in-licensed in 2020 from Santa Clara University USA and enables the addition of custom surface proteins to EVs for targeting to specific tissues. Our LOAD technology, in-licensed from the State University of New York at Buffalo USA, enables us to load EVs with specialised therapeutic cargo.
Naïve EV Program
Exopharm is developing naïve (or natural) EVs (NEVs) from adult stem cells and platelets as regenerative medicine products. NEVs have the potential to deliver the natural regenerative benefits of cells without the challenges of administering cells to patients. Exopharm’s two main NEV products are called Plexaris™ (from platelets) and Cevaris™ (from adult stem cells).
Exopharm was the first company to bring a proprietary naïve EV drug into the clinic; a milestone enabled by our LEAP Technology for the manufacture of clinical-grade EVs rapidly and at large scale.